LYSA (the lymphoma research group) has just launched the 1st French academic study of CAR-T cells. Named ALYCANTE, this study... View Article
Author Archives for Adeline Chauvigné
Research | CAR-T cells are revolutionising cancer treatment
4 November 2025LYSA (the lymphoma research group) has just launched the 1st French academic study of CAR-T cells. Named ALYCANTE, this study... View Article
Treatment of aneurysms and strokes (CVA): Rennes University Hospital has acquired a new-generation interventional imaging platform
Because every minute counts when a person suffers a stroke (CVA), since the start of the year Rennes University Hospital... View Article
Treatment of aneurysms and strokes (CVA): Rennes University Hospital has acquired a new-generation interventional imaging platform
4 November 2025Because every minute counts when a person suffers a stroke (CVA), since the start of the year Rennes University Hospital... View Article
Prevention, diagnosis, treatment: the power of Microbiota
Microbiota, a genuine repository of our lifestyle, is a key part of our health and Atlanpole Biotherapies has made it... View Article
Prevention, diagnosis, treatment: the power of Microbiota
4 November 2025Microbiota, a genuine repository of our lifestyle, is a key part of our health and Atlanpole Biotherapies has made it... View Article
Françoise Le Vacon
As a scientist in perpetual motion and endowed with inexhaustible energy, she has been developing her expertise in the field... View Article
Françoise Le Vacon
4 November 2025As a scientist in perpetual motion and endowed with inexhaustible energy, she has been developing her expertise in the field... View Article
OSE Immunotherapeutics enters into global license agreement in the organ transplantation market
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in... View Article
OSE Immunotherapeutics enters into global license agreement in the organ transplantation market
4 November 2025OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in... View Article
CELIS Challenges? Are you up to it?
In the framework of our European project CE4BIG, we have developed a collaboration with the European project CELIS, which is... View Article
CELIS Challenges? Are you up to it?
4 November 2025In the framework of our European project CE4BIG, we have developed a collaboration with the European project CELIS, which is... View Article
GlioCure transforms into a Limited Liability Company and closes a new round of financing
GlioCure, a preclinical-drug-development company specialized in neuro-oncology, announced today that during a recent combined general meeting, its shareholders ratified transformation... View Article
GlioCure transforms into a Limited Liability Company and closes a new round of financing
4 November 2025GlioCure, a preclinical-drug-development company specialized in neuro-oncology, announced today that during a recent combined general meeting, its shareholders ratified transformation... View Article
Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article
Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
4 November 2025Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article
Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
4 November 2025Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
INRAE involved in a research project on non-hormonal female contraception
Accelerating Discovery for Non-Hormonal Contraceptives is one of the Grand Challenge programmes launched by the Bill & Melinda Gates Foundation... View Article
INRAE involved in a research project on non-hormonal female contraception
4 November 2025Accelerating Discovery for Non-Hormonal Contraceptives is one of the Grand Challenge programmes launched by the Bill & Melinda Gates Foundation... View Article